Sintilimab after surgery for liver cancer with microvascular invasion
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests whether the immunotherapy drug Sintilimab, given after surgery, can help prevent liver cancer from coming back in people whose tumors had tiny blood vessel invasion. It is for patients who have fully recovered from surgery and have not had other cancer treatments before.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You had surgery to remove your liver cancer, and your doctor confirmed it had microvascular invasion (tiny cancer cells in small blood vessels).
- You are between 18 and 75 years old.
- You have not had any prior cancer treatment (like chemotherapy, radiation, or targeted therapy) for this liver cancer.
- Your liver function is good (Child-Pugh score A or B7), and you are generally active (ECOG 0 or 1).
- You have fully recovered from surgery within the last 4 weeks and have no signs of cancer spread outside the liver.
- You do not have serious heart problems, uncontrolled high blood pressure, or a history of autoimmune disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a combination of two drugs (sintilimab and lenvatinib) given after surgery can help prevent liver cancer from coming back in people who had a tumor growing into the portal vein (a major blood vessel in the liver). You may join if you recently had successful surgery and haven't had other treatments yet.
This trial tests two drugs, sintilimab and bevacizumab, given before surgery to treat liver cancer that can be removed. It's for people with a certain stage of liver cancer who haven't had other treatments.
This trial tests a combination of immunotherapy (sintilimab), a targeted anti-angiogenic drug (bevacizumab biosimilar), and liver-directed therapies (TACE-HAIC) before and after surgery for hepatocellular carcinoma that has spread to the portal vein. The goal is to see if this approach improves outcomes for patients with advanced but resectable liver cancer.
This trial studies whether combining two medicines (tislelizumab and sitravatinib) given after curative liver cancer surgery can help prevent the cancer from coming back. It is for people with liver cancer at high risk of recurrence, who have fully recovered from surgery and have no spread beyond the liver.
This trial tests a combination of two drugs (lenvatinib and sintilimab) plus a procedure called SIRT (radioactive beads) for people with liver cancer that can't be surgically removed. The goal is to see if this triple approach works better than standard treatments.
This trial tests a combination of targeted radiation (SBRT) and immunotherapy for people with small liver cancers that have come back or are still present after prior treatment. It aims to see if this approach can better control the cancer without using heavy chemotherapy.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.